透過您的圖書館登入
IP:18.191.180.252
  • 期刊

【論文摘要】A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study

摘要


COVID-19 is a global pandemic, with over 50 million confirmed cases and 1.2 million deaths as of November 11, 2020. No therapies or vaccines so far are recommended to treat or prevent the new coronavirus. A novel traditional Chinese medicine formula, Taiwan Chingguan Yihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020. Its clinical outcomes and pharmacology have been evaluated. Among 33 patients with confirmed COVID-19 admitted in two medical centers, those (n = 12) who were older, sicker, with more co-existing conditions and showing no improvement after 21 days of hospitalization were given NRICM101. They achieved 3 consecutive negative results within a median of 9 days and reported no adverse events. Pharmacological assays demonstrated the effects of the formula in inhibiting the spike protein/ACE2 interaction, 3CL protease activity, viral plaque formation, and production of cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α. This bedside-to-bench study suggests that NRICM101 may disrupt disease progression through its antiviral and anti-inflammatory properties, offering promise as a multi-target agent for the prevention and treatment of COVID-19.

關鍵字

無資料

被引用紀錄


陳昭憲、張凱惟、曾元卜、龔彥穎、陳方佩(2022)。新冠肺炎中西醫整合治療經驗臨床醫學月刊89(2),95-99。https://doi.org/10.6666/ClinMed.202202_89(2).0017
邱榮鵬、黃建榮、黃伯瑜、許中華(2022)。中西醫專責醫院之韌性防疫源遠護理16(2),14-20。https://doi.org/10.6530/YYN.202207_16(2).0002
莊志瑜、張(王夋)瑛、鄭宏足(2022)。小陷胸湯合抵當湯治療COVID-19驗案二則中醫藥研究論叢25(),65-69。https://doi.org/10.6516/TJTCM.202203/SP_25.0009
吳建東(2022)。COVID-19後遺症之神經痛及嗅覺喪失恢復一例中醫藥研究論叢25(),51-57。https://doi.org/10.6516/TJTCM.202203/SP_25.0007
廖芳儀、林恭儀、黃建榮、周艷秋、Alexander T. H. Wu(2022)。大青龍湯與清冠一號遠距COVID-19治療與預防個案報告中醫藥研究論叢25(),13-20。https://doi.org/10.6516/TJTCM.202203/SP_25.0002

延伸閱讀